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ABSTRACT
DREAM (downstream regulatory element antagonist
modulator) is a transcriptional repressor, which
binds DREs (downstream response elements) in a
Ca21-regulated manner. The DREs consist of core
GTCA motifs, very similar to binding motifs for
non-steroid nuclear receptors. In this work, we find
that DREAM stimulates basal and ligand-dependent
activation of promoters containing vitamin D and ret-
inoic acid response elements (VDREs and RAREs),
consisting of direct repeats of the sequence AGT/
GTCA spaced by 3 or 5 nt, respectively. Stimulation
occurs when the element is located upstream,
but not downstream, the transcription initiation
site. Activation requires both Ca21 binding to the
EF-hands and the leucine-charged domains (LCDs),
analogous to those responsible for the interaction
of the nuclear receptors with coregulators. Further-
more, DREAM can bind both ‘in vitro’ and in chromatin
immunoprecipitation assays to these elements.
Importantly, ‘in vivo’ binding is only observed in
vitamin D- or RA-treated cells. These results show
that DREAM can function as an activator of trans-
cription on certain promoters and demonstrate
a novel role for DREAM acting as a potential modu-
lator of genes containing binding sites for nuclear
receptors.
INTRODUCTION
DREAM (downstream regulatory element antagonist modu-
lator) is a multifunctional Ca2+-binding protein, which acts as
a transcriptional repressor by binding as a tetramer to DREs
(downstream regulatory elements) located downstream of the
TATA box in target genes (1,2). DREs can be composed of a
single copy or two inverted copies of the sequence GTCA (3).
DREAM was first identified as a repressor for the prodynorphin
gene in neuroblastoma cells (1) and appears to play an import-
ant role in vivo in pain modulation (4).
DREAM contains four EF-hands, of which three are
responsible for binding of Ca2+ ions (1). Stimuli that increase
intracellular Ca2+ or cAMP levels cause the release of DREAM
from the DRE and transcriptional derepression. cAMP and
Ca2+ appear to promote derepression by different mechanisms.
Whereas Ca2+ modifies DREAM conformation by binding
to the EF-hand motifs, leading to release of DREAM from
the DRE (1,5), cAMP-dependent derepression involves a
direct protein–protein interaction of DREAM with a-CREM
(cAMP response element modulator) (6). The interaction with
a-CREM is Ca2+-independent and is governed by leucine-
charged domains (LCDs). Two LCDs in DREAM and two
LCDs located in the kinase-inducible domain (KID) of
a-CREM participate in a two-site interaction that results in
the loss of DREAM binding to the DRE and transcriptional
derepression (6). In addition, in the absence of Ca2+, DREAM
binds to LCDs located in the KID domain of cAMP response
element-binding protein (CREB). As a result, DREAM impairs
recruitment of the coactivator CBP (CREB-binding protein)
and blocks phospho-CREB-dependent transactivation (7).
In addition to the evidence indicating that DREAM is
a transcription factor (8), this protein might have pleio-
tropic functions through the interaction with specific DNA
sequences and/or with diverse proteins in different cell com-
partments (9–11).
Nuclear receptors are ligand-dependent transcription fac-
tors, which regulate gene expression by binding to HREs
(hormone response elements) located in regulatory regions of
target genes (12). In the case of the vitamin D receptor (VDR)
or the retinoic acid receptor (RAR), these elements contain the
*To whom correspondence should be addressed. Tel: +34 91 5854453; Fax: +34 91 5854401; Email: aaranda@iib.uam.es
ª The Author 2005. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oupjournals.org
Nucleic Acids Research, 2005, Vol. 33, No. 7 2269–2279
doi:10.1093/nar/gki503
consensus sequence PuGGT/GTCA, which is rather similar to
the DRE. A direct repeat (DR) of this sequence spaced by 3 nt
(DR3) acts as a response element for vitamin D (VDRE),
whereas a DR2 or a DR5 act as retinoic acid response elements
(RAREs). Heterodimerization of VDR and RAR with the
retinoid X receptor (RXR) increases affinity for DNA and
transcriptional activity (13).
The effects of nuclear receptors on transcription are medi-
ated through recruitment of coregulators. In the absence of
ligand, the receptors can repress target gene expression (14)
because they bind corepressors, such as silencing mediator for
retinoid and thyroid hormone receptors (15) or nuclear recep-
tor corepressor (16) assembled in complexes that include
histone deacetylases. Upon ligand binding corepressors are
released and coactivator complexes are recruited. Coactivators
cause chromatin decompactation, RNA polymerase II recruit-
ment and transcriptional activation (12,17–19). Interaction
of nuclear receptors with coactivators and corepressors is
also dependent on LCDs. The LCD motif LXXLL, where
X denotes any amino acid, was first described in nuclear hor-
mone receptor p160 coactivators (20,21). Three copies of this
signature motif, present in the receptor interacting domain
(RID) in the coactivator proteins, mediate association with
the receptors. Furthermore, LCDs in the N- and C-terminal
domains of the coactivator CBP mediate interaction of this
protein with the receptors and p160 proteins, respectively (21).
The receptor-interacting domain (CoRNR box) of the
corepressors possesses the LCD motif L/IXXV/II, which is
sufficient for corepressor binding and ligand-induced release
(22–24). The LCDs in a-CREM (ILNEL and LIEEL) have an
antiparallel orientation compared with the motifs responsible
for the association of coregulators with nuclear receptors and
define a third type of LCD (6).
The homology between the DNA sequences recognized by
DREAM and the nuclear receptors, as well as the presence of
LCDs in DREAM, led us to examine the existence of a pos-
sible cross-talk between the receptors and this transcriptional
repressor. Our results show that DREAM can bind to HREs
and that, unexpectedly, can act as a transcriptional activator
and increase ligand-dependent transactivation of constructs
containing these motifs, when located upstream the transcrip-
tion initiation site. Interestingly, the DREAM LCD appear to
be required for this stimulation, suggesting that protein–
protein interactions are also involved in this stimulation. Con-
versely, nuclear receptors can bind to DREs, although this
binding is transcriptionally unproductive. These results dem-
onstrate a novel role for DREAM acting as a modulator of
nuclear receptor-mediated responses.
MATERIALS AND METHODS
Plasmids
Luciferase reporter plasmids containing different fragments of
the human RARb2 promoter have been described previously
(25). R140, R90 and R37 includes fragments 124 to +14,
59 to +14 and11 to +34 (26). In R140M3 and 140M7, the 30
and 50 half-sites of the RARE have been mutated, respectively.
The VDRE was cloned upstream of the thymidine kinase (TK)
promoter of pBL-CAT8+ to give DR3-TK (27). TK-DR3-
CAT was constructed by cloning the VDRE sequence in the
SalI site downstream of the TK promoter in the same vector.
CAT plasmids TK-DRE and DRE-TK have been described
previously (2). pHD3 contains the sequence 151 to +150 of
the human prodynorphin promoter (2). A luciferase reporter
plasmid containing 2.3 kb of the p21Cip1 promoter cloned in
pGL3 (Promega) was also used. Expression vectors for VDR
and RARa are cloned in pSG5 (27). Expression vectors for
wild-type DREAM and mutants in the EF-hands and in the
LCDs (L47,52V and L155V) have been described elsewhere
(1,6). Constructs in which the GAL4 DNA-binding domain
(DBD) is fused to the ligand-binding domain (LBD) of RAR
and VDR were a kind gift from R. Evans. These constructs
were transfected together with a luciferase reporter UAS plas-
mid containing binding sites for the GAL-DBD.
Cell culture and transfections
HeLa, GH4C1 and HL-60 cells were grown as previously
described in DMEM containing 10% fetal calf serum
(28,29), and SK-N-MC cells in DMEM-Ham F-12 medium
with the same amount of serum (2). The cells were transfected
by calcium phosphate with 5 mg of reporter plasmids and
5 mg of the expression vectors indicated in the legends for
Figures 1–4 and 6–8. The amount of DNA was always kept
constant by the addition of the appropriate amount of a non-
coding empty vector. After transfection, the cells were incub-
ated for 24–36 h in the presence and absence of 100 nM
vitamin D (Vit.D) or 1 mM all-trans-retinoic acid (RA) in
medium supplemented with 10% AG1-X8 resin and
charcoal-stripped newborn calf serum. Results are shown as
fold induction over the values obtained in untreated cells in the
absence of transfected DREAM. All data shown are
mean – standard deviation of CAT or luciferase activities
from at least five independent experiments in triplicates.
Gel mobility shift assays
Recombinant DREAM, glutathione S-transferase (GST)-fused
VDR and RXR (50–100 ng) and in vitro translated RXR, VDR
and RAR were used in the assays with labeled DRE, DR3 and
DR5 oligonucleotides as described previously (30). Mock lys-
ates of GST alone or unprogrammed reticulocyte lysates were
used in control lanes. For competition experiments, a 30-fold
excess of unlabeled oligonucleotides encompassing the DRE,
DR3 or a consensus Sp-1 binding site were added to the bind-
ing reactions. For supershift experiments, a monoclonal anti-
body against DREAM (2 ml) (6) was added before the addition
of the labeled probe. When indicated 10 mM CaCl2 was present
in the incubation reaction. Analysis of coactivators recruit-
ment by receptor heterodimers were performed with in vitro
translated receptors (3 ml) and 600 ng of the RIDs of the p160
coactivators: steroid receptor coactivator 1 (SRC-1) (31),
activator for thyroid and retinoid receptor (ACTR) (32) and
transcription intermediary factor-2 (TIF-2) (33), fused to GST.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation (ChIP) assays were per-
formed essentially according to a previously published method
(34). Approximately 2 · 108 HL-60 cells, grown with charcoal-
stripped serum for 12–36 h, were treated with 100 nM Vit.D
or 1 mM RA for 2 h, or were left untreated. The cells were
cross-linked for 10 min with 1% paraformaldehyde, nuclei
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were collected and the chromatin was sonicated to an average
length of between 500 and 2000 bp. After preclearing with
protein A/G Sepharose (Amersham), blocked with salmon
sperm DNA, BSA and in the presence of preimmune rabbit
IgG (Sigma), aliquots of the chromatin was immunoprecipit-
ated with aDREAM (10 mg, affinity-purified polyclonal anti-
body 1013), aAcH4 (5 ml, Upstate 06-866), aSRC1 (12 mg;
Santa Cruz SC-20) or, as a negative control, preimmune rabbit
IgG (10 mg). Capturing of the immunecomplexes, washing and
reversal of cross-linking was carried out exactly as described.
Thereafter, the immunoprecipitated DNA and an aliquot of the
precleared chromatin (input) were purified using Qiagen PCR
purification columns (in the presence of a carrier, tRNA).
DNA was subjected to semi-quantitative PCR in the linear
range (22–24 cycles) in the presence of a trace amount of
[a-32P]dCTP. The primers used were: for the human p21Cip1
promoter containing the VDRE (located at 788/756)
forward 50-GGCTATGTGGGGAGTATTCAG-30 and reverse
50-CCAGGGAAACAGAAGAATTGGACA-30 (156 bp), for
the human p21Cip1 promoter containing the RARE (located at
1221/1194) forward 50-GGTCAGGGGTGTGAGGTAG-30
and reverse 50-GATCATGCAGCAAAGAAATGACTA-30
(248 bp), and for the RARb2 promoter containing the
RARE (located at 37/53) forward 50-CTGGGAGTTGGT-
GATGTCAGACTA-30 and reverse 50-TGGCAAAGAATA-
GACCCTC-30 (168 bp). As a negative control, a GAPDH
promoter fragment (174 bp) was amplified with the forward
50-AGGGTTGCCACTGGGGATCT-30 and reverse 50-TGCC-
AAAGCCTAGGGGAAGA-30 primers. PCR fragments were
analyzed by polyacrylamide gels and autoradiography. Quan-
tification was obtained using the NHI Image software. Results
obtained were corrected by the input and are expressed as fold
induction of vitamin D or RA-treated versus untreated cells.
RESULTS
DREAM stimulates VDRE-mediated transcription
To analyze whether DREAM could bind to HREs, gel retarda-
tion assays were performed with a probe encompassing a DR3
site, a high-affinity element for RXR/VDR heterodimers.
As shown in Figure 1A, recombinant DREAM bound to the
DR3 with a stronger affinity than to the consensus DRE of
the prodynorphin gene (compare lanes 3 and 6). Association of
DREAM to both the DRE and the DR3 was competed with
an excess of either unlabeled oligonucleotide, whereas a non-
related competitor did not affect retardation (Figure 1B). Also
showing the specificity of the binding of DREAM to the DR3
sequence, an anti-DREAM antibody caused a supershift of
the DREAM-DR3 retarded band (Figure 1C). Furthermore,
association of DREAM with the VDRE was sensitive to
Ca2+, decreasing when CaCl2 was present in the binding buffer
(Figure 1D).
Conversely, binding of the receptor heterodimer VDR/RXR
to the DRE was also observed, although with a lower affinity
than to the VDRE (Figure 1A, lanes 2 versus lane 5). Figure 1E
compares binding of VDR and RXR with the DR3 and the
DRE. Both VDR and RXR were able to interact with the DR3
and, as expected, heterodimerization significantly increased
binding. In the case of the DRE, VDR or RXR alone did not
cause retardation, but a strong binding of heterodimers was
found (lane 8). Therefore, although only one binding motif is
present in the DRE, heterodimers but no receptor monomers
associate with this element.
To explore the possibility that DREAM could regulate the
activity of VDRE-containing promoters, we used transient
transfection assays in HeLa cells with CAT reporter plasmids,
in which the VDRE sequence was cloned both upstream or
downstream of the TK minimal promoter. HeLa cells possess
endogenous VDR, but do not express DREAM (2,28). As
shown in Figure 2A, expression of DREAM did not signific-
antly affect the activity of the empty TK reporter, confirming
previous results (2). Surprisingly, DREAM, however, strongly
increased the basal activity of the DR3-TK-CAT plasmid, and
this activity was further enhanced in the presence of vitamin D.
Therefore, in this context DREAM does not act as a repressor,
but as an activator of VDRE-dependent transcription. Import-
antly, activation by DREAM depends on the position of the
VDRE site because DREAM was unable to affect the activity
of a construct in which the DR3 is located downstream of the
TK promoter. This plasmid is also insensitive to vitamin D
(Figure 2A).
To further investigate a relationship between vitamin D
responsiveness and the activation of VDRE-dependent
Figure 1. DREAM binds to a DR3 vitamin D response element. (A) Gel
retardation assays performed with 100 ng of DREAM and 50 ng of GST-
fused VDR and RXR and the DR3 and DRE oligonucleotides. (B) Binding
of 50 ng of DREAM to these oligonucleotides was competed with excess of
DRE, DR3 and Sp-1 oligonucleotides. (C) Binding of DREAM to the DR3 was
supershifted with 2 ml of a DREAM antibody (aDREAM). Mobility of the
super-retarded complex is indicated by an arrow. (D) Binding of DREAM to the
DR3 was performed in the absence and in the presence of 10 mM CaCl2. (E)
Binding of recombinant VDR and RXR (100 ng) alone and in combination with
the DR3 and DRE oligonucleotides.
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transcription by DREAM, we performed DR3-TK-CAT
reporter assays in pituitary and neuroblastoma cells, which
in contrast with HeLa cells express DREAM (2,35). In addi-
tion to expressing DREAM, pituitary somatolactotrop cells
contain endogenous VDR and are responsive to vitamin D
(27). Overexpression of DREAM in GH4C1 cells caused an
increase in basal reporter activity, though less pronounced than
that observed in HeLa cells that lack this factor, and signific-
antly enhanced the ligand-dependent response (Figure 2B).
These results indicate that the endogenous DREAM levels
are not sufficient to produce a maximal stimulation of the
VDRE-containing promoter. Interestingly, in neuroblastoma
SK-N-MC cells, which express high DREAM levels (2), over-
expression of DREAM failed to increase basal activity of
the DR3-TK-CAT reporter (Figure 2B). We have previously
shown that endogenous DREAM activity in SK-N-MC cells
failed to modify the activity of a DRE-TK-CAT reporter
while repressed a TK-DRE-CAT reporter (2). In these cells,
vitamin D did not increase the reporter activity, demonstrating
that VDR levels are not sufficient to elicit a significant
transcriptional response.
DREAM activates RARE-dependent transcription
To analyze whether DREAM could also influence RARE-
dependent transcription, HeLa cells were transfected with rep-
orter plasmids containing different fragments of the RARb2
promoter. This promoter contains a well-characterized RARE,
configured as a DR5 between nucleotides 37 and 53
(Figure 3A), which binds RXR/RAR heterodimers (26). As
illustrated in Figure 3B, DREAM significantly stimulated the
activity of the constructs R140 and R90, which contain the
RARE, and also potentiated the response to RA in HeLa cells.
Interestingly, mutation of either the 50 (R140M3) or the 30
(R140M7) motifs of the DR5 was sufficient to strongly reduce
RA-dependent transactivation but did not block stimulation
by DREAM. Nevertheless, the RARE mediates the effect of
DREAM on the promoter, since reporter plasmid R37, in
which this element has been deleted, was not significantly
stimulated by DREAM. This suggests that the requirements
for DREAM and RXR/RAR heterodimer binding to these
sequences are different and that whereas both hemisites of
the response element are required for stimulation by RA,
only one hemisite is sufficient for stimulation by DREAM.
Figure 3C compares the influence of DREAM on the activ-
ity of the RARb2 promoter in HeLa, GH4C1 and SK-N-MC
cells. These cells are known to contain RA receptors and
are responsive to the retinoid. As occurred with the DR3-
containing promoter, DREAM was able to increase the activity
of the R90 construct in HeLa and GH4C1 cells, but not in the
neuroblastoma cells, that already express high endogenous
DREAM levels. In addition, RA stimulated the activity of the
RARb2 promoter to a similar extent in HeLa and SK-N-MC
cells and less strongly in GH4C1 cells, but DREAM was able
to enhance RA-dependent activation in all cell types. Similar
Figure 2. DREAM stimulates VDRE-dependent transcription. (A) HeLa
cells were transfected with reporter CAT plasmids containing the DR3 element
cloned upstream and downstream of the thymidine kinase promoter (DR3-TK
and TK-DR3, respectively). A TK-CAT plasmid, which does not contain the
response element, was also used as a control. The reporter constructs were
cotransfected with an expression vector for DREAM or the corresponding
empty vector, and CAT activity was determined after 36 h of treatment in
the absence and presence of 100 nM Vit.D. (B) CAT activity was determined
in untreated and vitamin D-treated HeLa, GH4C1 and SK-N-MC cells cotrans-
fected with the DR3-TK reporter and expression vectors for wild-type DREAM.
Figure 3. DREAM stimulates RARE-dependent transcription. (A) Schematic
representation of mutations and deletions in the RARb2 promoter, showing the
positions of the RARE, the TATA box and the Initiator (Inr). The hemisites
in the RARE are indicated by arrows. In R140M3 and R140M7, the 50 and 30
motifs, respectively, of the RARE have been mutated and mutations are shown
as X. (B) HeLa cells were transfected with the RARb2 luciferase reporter
constructs indicated and an expression vector for DREAM or the noncoding
vector. (C) HeLa, GH4C1 and SK-N-MC cells were transfected with the R90
construct and the expression vector for DREAM. Reporter activity was deter-
mined in cells incubated in the presence and absence of 1 mM all-trans-RA.
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results were obtained with the R140 construct (not illustrated).
Therefore, in several cellular contexts, DREAM appears to act
as an activator of reporters containing DR5 and DR3 elements
upstream of the TATA box.
DREAM is recruited in vivo to HRE-containing
promoters in a ligand-dependent manner
It has been shown that p21Cip1 expression is stimulated by both
vitamin D and RA in hematopoietic cells (36,37), and there-
fore this gene constitutes a good model for analyzing the
effects of DREAM. To study the response of the p21Cip1
promoter to DREAM, a reporter plasmid containing the
50-flanking region of the p21Cip1 gene was transfected into
HL-60, HeLa, pituitary and neuroblastoma cells in the pres-
ence and absence of DREAM. In addition, the effect of a
version of DREAM (EF-LCDmut), in which both the Ca2+-
binding domain and the LCDs were mutated (3), was also
examined. The difficulty of transfection of hematopoietic
cells did not allow the study of the effect of DREAM on
the p21Cip1 promoter in HL-60 cells. However, as shown in
Figure 4, native DREAM, but not the mutated protein, strongly
stimulated the p21Cip1 promoter in HeLa cells. In agreement
with the data obtained with the RARb2 and the DR3-
containing promoters, DREAM was less effective in GH4C1
cells and again did not stimulate the promoter activity in
SK-N-MC cells that contain high endogenous DREAM levels.
The EF-LCDmut was also uneffective in pituitary and neuro-
blastoma cells. In the tested cell types, we did not observe
activation of the p21Cip1 promoter by vitamin D or RA (data
not shown).
The p21Cip1 promoter contains a VDRE and a RARE at
positions 770 and 1200, respectively. To analyze binding
of DREAM to these sites ‘in vivo’, we carried out ChIP assays
with primers amplifying the p21Cip1 promoter fragments that
include the VDRE or the RARE motifs. The distance between
both elements allows the study of recruitment of DREAM to
these elements separately. For these studies, we used hema-
topoietic HL-60 cells that contain high levels of DREAM
(not illustrated), and in which incubation with vitamin D or
RA increases p21Cip1 expression and induces differentiation
(36,37). Binding of DREAM to the proximal RARb2 promoter
was also determined by ChIP assay in these cells. Fragments
encompassing the VDRE and RARE (Figure 5A) of the
p21Cip1 promoter were not amplified above the levels obtained
with a non-specific antibody from chromatin of untreated cells
after immunoprecipitation with an anti-DREAM antibody.
However, DREAM was recruited to the VDRE promoter
region in cells incubated with vitamin D and to the RARE
promoter region in RA-treated cells (compare lanes 5 and 6).
Similarly, ‘in vivo’ binding of DREAM to the fragment
encompassing the RARE of the RARb2 gene was only detec-
ted upon incubation with the retinoid (Figure 5B). As shown
in Figure 5C, incubation of HL-60 cells with either RA or
vitamin D also caused the recruitment of acetylated histone
H4 to the p21Cip1 promoter fragments containing the RARE
and the VDRE, respectively. In contrast, acetylated histone H4
was not found after vitamin D treatment in the promoter of the
GAPDH gene, used as a negative control. An antibody against
the p160 coactivator SRC-1 was also used in ChIP experi-
ments. In parallel with the increase in acetylated H4 histone
and DREAM, RA and vitamin D also caused the recruitment
of the coactivator to the RARE or VDRE p21Cip1 promoter
regions (Figure 5D).
The LCDs are required for DREAM-dependent
stimulation of the DR3 and DR5-containing plasmids
Since binding of DREAM to DREs and repression is blocked
in the presence of Ca2+ (1), we examined the influence of
a DREAM mutated protein (EFmutDREAM) in which the
three functional EF-hands of DREAM were modified. EFmut-
DREAM binds to DREs and like wild-type DREAM is regu-
lated by cAMP (3). EFmutDREAM failed to activate the basal
expression of the DR3TK reporter (Figure 6B) and even had an
inhibitory effect on the basal activity of the RARb2 promoter
construct (Figure 6C). Furthermore, the mutant also failed to
potentiate ligand-dependent transactivation of either reporter
by vitamin D or RA, respectively. The fact that DREAM and
EFmutDREAM show different effects on the HRE-dependent
transcription suggest that not only protein–DNA but also
protein–protein interactions could be involved in the complex
regulation by DREAM of VDRE- and RARE-mediated gene
expression. To test the importance of these interactions in the
transactivating effect of DREAM on hormone receptor medi-
ated transcription, we used DREAM with mutations at the
LCDs (Figure 6A) and assessed their activity on the DR3-
TK and R-140 reporters in HeLa cells. Figure 6 shows that
although wild-type DREAM causes activation of the DR3- and
DR5-containing promoters, DREAM mutants bearing the
mutations L47,52V in the first LCD or L155V in the second
LCD did not activate basal or ligand-dependent expression of
the DR3 and RARb2 promoters. Mutation of the Ca2+-binding
motifs in combination with both LCDs (EF-LCDmut)
did not further repress ligand-independent or -dependent
transcription. Therefore, any of the single mutations alone is
enough to preclude the effect of DREAM on transcriptional
Figure 4. DREAM activates the p21cip1 promoter. A luciferase reporter
plasmid containing 2.3 kb of the 50-flanking region of the p21cip1 gene was
transfected into HeLa, GH4C1 and SK-N-MC. Reporter activity was deter-
mined in cells transfected with an empty vector or with expression vectors
for wild-type DREAM or for a DREAM protein, in which both the functional
EF-hands and the LCDs have been mutated (EF-LCDmut).
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activity mediated by the HREs. These results further sub-
stantiate the idea that protein–protein interactions that are
disturbed upon changes in the DREAM protein could be
involved in DREAM-dependent transactivation of HRE-
mediated transcription.
Since the LCDs in DREAM are similar to those present in
several nuclear receptor coactivators, we tested the possibility
that DREAM could form a complex with the receptor heterodi-
mers when bound to DNA. However, as shown in Figure 7A,
the receptors and DREAM appear to bind independently to the
DR3 or DR5 elements, since neither the formation of larger
complexes by occupancy of the same DNA molecule nor the
appearance of complexes with intermediate mobilities due to
the interaction of DREAM with the receptors was detected. In
addition, binding of in vitro translated DREAM with VDR or
RAR fused to GST was analyzed in pull-down assays. No
direct interaction of the receptors with DREAM was observed,
whereas in the same assays hormone receptors interacted in a
ligand-dependent manner with a p160 coactivator used as a
positive control (data not shown). Thus, DREAM can cooper-
ate with vitamin D and RA to increase HRE-dependent tran-
scription without a direct interaction with their receptors.
To test directly whether DREAM could affect ligand-
dependent and -independent transactivation without binding
of the receptor heterodimers to their recognition sites on DNA,
we performed transfection studies in which fusions of the
DBD of the yeast transcription factor GAL4 with the LBDs
of VDR and RAR were cotransfected with expression vectors
for wild-type and mutant DREAM and a reporter UAS plas-
mid. As shown in Figure 7B, expression of neither native
DREAM nor the EF-LCDmut affected significantly the activ-
ity of GAL-VDR or GAL-RAR in the absence of ligand.
In addition, DREAM caused a weak increase of the ligand-
dependent response, which was absent when the EF-LCDmut
DREAM was used. These data further demonstrate that the
presence of the HRE plays an important role in the transactiv-
ating effects of DREAM.
Nuclear receptors do not affect DRE-dependent
transcription
Since RXR/VDR heterodimers bind the DRE as shown in
Figure 1, we next examined the possibility that vitamin D
could influence the activity of constructs containing this
Figure 5. DREAM binds in vivo to the p21cip1 promoter. (A) Schematic representation of the 50-flanking region of the p21cip1 gene showing the location of the primers
used to amplify the fragments that contain the VDRE and the RARE used in the ChIP assays. The assays were performed in untreated HL-60 cells and in cells treated
with vitamin D or RA for 2 h. Representative assays for both regions performed with control and anti-DREAM antibodies are shown in the lower panels. The inputs of
the assays for untreated and treated cells are shown in lanes 1 and 2, respectively. (B) The upper panel shows the position of the RARE of the RARb2 promoter and the
region amplified in the ChIP assays in control and RA-treated cells is shown in the lower panel. In (C), ChIP assays were performed with an antibody against
acetylated histone H4 (aAcH4). In the left panel are shown the results obtained with the regions amplifying the RARE and the VDRE of the p21cip1 gene in cells
treated with RA and vitamin D, respectively. The right panel illustrates the amplification of a GAPDH promoter fragment, used as a negative control, in control and
vitamin-D treated cells. (D) Recruitment of the p160 coactivator SRC-1 to the RARE and VDRE regions of the p21cip1 promoter in control cells and after treatment
with RA or vitamin D, respectively. In all panels, relative recruitment in untreated versus ligand-treated cells was quantified and is shown as fold induction.
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element. For this purpose, HeLa cells were transfected with the
CAT reporter plasmid HD3. This construct contains the pro-
dynorphin promoter fragment 151 to +150 with the DRE at
position +40. As illustrated in Figure 8A, vitamin D did not
alter the activity of the prodynorphin promoter. Since the
affinity of binding of the receptor to the DRE was lower
than to a DR3, the CAT activity was also examined after
the overexpression of VDR. Expression of the receptor caused
some ligand-dependent increase of pHD3 activity. However,
this effect appears to be independent of the DRE, as mutation
of this element did not alter regulation by VDR. Similar results
were obtained after treatment with RA that did not alter the
activity of the prodynorphin promoter even after the over-
expression of RAR (Figure 8B).
The possibility that VDR could stimulate DRE-dependent
transcription when this element is located upstream of the
transcription initiation site was also explored. Figure 8C com-
pares the results obtained in cells transfected with constructs
in which the DR3 and DRE elements are cloned both 50 and 30
of the TK promoter. Only the activity of the DR3-TK construct
was stimulated by vitamin D, both in the presence and in
the absence of transfected receptor. In contrast, the DRE
was unable to sustain VDR-mediated transcriptional activity.
Since ligand-dependent stimulation by nuclear receptors
depends on recruitment of coactivators, we next examined
binding of several p160 coactivators, including SRC-1,
ACTR and TIF-2 to receptors bound to the DR3 and DRE
motifs. As shown in Figure 9, addition of ligand caused strong
recruitment of coactivators by the RXR/VDR heterodimers
bound to the DR3, which was shown by the appearance of
a super-retarded complex. However, intensity of this band was
much less prominent when the receptors were bound to the
DRE, and the supershifted bands were only detected after
longer exposures.
DISCUSSION
In this work, we show that the repressor DREAM can also
function as a transcriptional activator of genes containing
response elements for nuclear receptors, such as VDR or
RAR. DREAM expression had a very strong stimulatory effect
on HRE-dependent transcription in cells that do not express
this factor, but was weaker in cells expressing high endo-
genous levels of DREAM protein. DREAM can bind in vitro
to these elements, and it can also bind in vivo, in a ligand-
dependent manner, to promoters of genes that contain a VDRE
or a RARE. Moreover, expression of DREAM strongly poten-
tiates ligand-dependent transcriptional regulation by VDR and
RAR. Therefore, depending on the promoter context, DREAM
functions as a repressor or as a transcriptional activator.
Our results show that DREAM can bind to HREs in vitro
even more efficiently than to the original DRE from the pro-
dynorphin gene (1). HREs are composed of two copies of
a hexameric motif rather similar to the DRE, and the presence
of two motifs probably contributes to the stabilization of
DREAM binding to these sequences. Natural DREs containing
two copies of the DRE motif have been found in the c-fos
and CREM genes (1,3,38). Analysis of these tandem DRE
sequences also showed a greater affinity for DREAM than
the prodynorphin DRE (3). Moreover, our results indicate
that the DRE motif can also function in a DR arrangement
and show the flexibility of DREAM binding to DNA, since this
factor can recognize sequences with different spacing between
the binding motifs. The fact that DREAM binds to DREs as
a tetramer may contribute to this flexibility. In addition to
Figure 6. Both the EF-hands and the LCDs are required for DREAM stimula-
tion of VDRE and RARE-containing promoters. (A) Schematic representation
of the DREAM protein showing the position of the two LCDs and the four
EF-hands. EF-LCDmut has mutations in the three functional EF-hands and in
both LCDs, EFmut is a mutant in the EF-hands. L47,52V and L155V are
mutants in the first and second LCD motifs in DREAM, respectively. Mutations
are indicated by asterisks below the corresponding domains. DR3-TK (B) and
R140 (C) reporter constructs were transfected into HeLa cells together with
expression vectors for wild-type (wt) and mutated versions of DREAM.
Reporter activity was determined after 36 h incubation in control cells and
in cells treated with vitamin D or RA.
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spacing, small differences in the half-site motif and in the
sequence of the flanking extensions of the response elements
appear to be important parameters in determining the binding
efficiency both for DREAM and for nuclear receptors (3,39).
Nevertheless, stimulation of HRE-mediated transcription by
DREAM and the nuclear receptors appears to have distinct
requirements. Thus, mutational analysis of the RARb2 pro-
moter shows that although stimulation by RA requires both
hemisites of the response element, only one hemisite is suf-
ficient for ligand-independent transactivation by DREAM.
The DREs of the prodynorphin and c-fos genes are located
downstream of the transcription initiation site (1,2). Further-
more, the DRE sequence of the apoptotic hrk gene is located in
the 30-untranslated region (30-UTR) (40). Here, we demon-
strate that DREAM was effective in stimulating a VDRE-
containing construct when the element was placed upstream
but not downstream of the TK promoter. These results
demonstrate that the position of the response element can
determine the transcriptional outcome. This was also true
for vitamin D-dependent activation that was only found
when the element was located upstream of the promoter.
Indeed, most positive HREs have this location. However,
nuclear receptors can mediate transcriptional repression in
a ligand-dependent manner through binding to the so-called
negative HREs. Interestingly, a rather common finding is that
these elements are positioned downstream of the transcription
initiation site (12,41), or even have an unusual location at the
30-UTR (42).
In contrast with the nuclear receptors that possess a well-
characterized DBD, this functional domain has not yet been
fully delineated in DREAM. DREAM appears to bind the DRE
as a tetramer, and most likely, the DBD is composed upon
oligomerization. Therefore, it has not been possible to analyze
the role of specific mutations in DREAM that abolish binding
to DNA on HRE-mediated transcriptional activation. How-
ever, we have found that DREAM proteins in which the
EF-hands or the LCDs have been mutated (1) fail to stimulate
HRE-dependent transcription. This is contrary to expectations
based on the similar efficiency of these mutants and wild-type
DREAM to bind DRE sites in the DNA (3,6,7). Furthermore,
in basal conditions, these mutants are as active as the wild-
type protein in repressing DRE-dependent transcription and
remain bound to DNA acting as dominant negative repressors
following Ca2+ or cAMP stimulation (1,3,7). Therefore, HRE-
dependent transcription requires the integrity of the EF-hands.
The finding that mutation of either LCD in DREAM abol-
ishes stimulation mediated by the HREs indicates that the
interaction of DREAM with the transcriptional complex
formed on the HRE site could be crucial for the transactivating
effect of this factor. A prevalence of protein–protein interac-
tions over binding of DREAM to DNA has been previously
reported in the de-repression of DRE sites following cAMP
stimulation, which depends on the interaction of DREAM with
a- or e-CREM (6) and in the repression by DREAM of CRE-
dependent transcription (7). In both instances, the protein–
protein interactions are mediated by the LCDs in DREAM
and in the CREM or CREB proteins. Although DREAM
binds in vitro to the HREs independently of the presence of
the occupied receptors, ChIP assays demonstrated that in vivo
binding could only be detected upon incubation of cells with
the appropriate ligand. The ligand-dependent recruitment of
DREAM parallels that of the nuclear receptor coactivators
and the increase of acetylated histones to the target promoter.
It is possible that the concentrations of DREAM used in the
retardation assays is sufficient to detect interactions, whereas
under physiological conditions DREAM could only be
recruited to the promoter through a direct interaction with
other proteins. One possible mechanism was that DREAM
could be tethered to the HRE through interaction with
the occupied receptor. However, despite the presence in
DREAM of LCDs rather similar to those responsible for
the association of coregulators with the nuclear receptors
(20–24), we did not observe a direct interaction of the recept-
ors with DREAM. Furthermore, we did not find a substantial
Figure 7. DREAM does not interact directly with the receptors. (A) Gel retardation assays performed with the DR5 and DR3 oligonucleotides. DREAM (50 ng) was
incubated with the probes alone or in combination with in vitro translated RAR and RXR (4 ml) or with recombinant VDR and RXR (100 ng), as indicated. (B) The
GAL-DBD alone or fused with the VDR or RAR LBDs were transfected into HeLa cells together with expression vectors for wild-type or EF-LCDmut DREAM and
the UAS reporter plasmid. Luciferase activity was determined after 24 h in untreated cells and in cells treated with vitamin D or RA, as indicated.
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increase in VDR- or RAR-mediated transactivation by
DREAM when these proteins are not bound to a HRE. There-
fore, recruitment to the HRE and activation of DR3- and
DR5-dependent transcription by this factor does not involve
a direct association with the receptors and appears to require
DREAM–DNA interactions. Future studies will determine
whether the association of DREAM with coactivators through
the LCDs could mediate the recruitment of DREAM to the
mediator complex that results in the potentiation of HRE
transcription by DREAM.
We also show here that VDR can bind to the prodynorphin
DRE, although with less affinity than to a VDRE. However,
this binding appears to be transcriptionally unproductive
because VDR was unable to influence DRE-mediated tran-
scription. The same was true for RAR. Therefore, there is a
discrepancy between the in vitro binding to the DRE and the
lack of transcriptional activation. This situation is similar to
that found with the RXR/RAR heterodimer bound to a DR1
(43), or the RXR/VDR heterodimer bound to a DR5 (44),
which cannot trigger transcriptional activation through these
elements. The receptor heterodimers bind to their bona fide
HREs with a strict polarity. Thus, on DR3 and DR5, RXR
occupies the 50 half-site and the corresponding partner (e.g.
VDR or RAR) occupies the 30 half-site (45–47). This particu-
lar arrangement permits RAR and VDR upon ligand binding to
undergo conformational changes that facilitate the recruitment
of coactivator complexes. However, it has been demonstrated
that in the cases of unproductive binding the heterodimer
associates to DNA with a reversed or undefined polarity
(43,44). The fact that the DRE is composed of a single
motif could prevent anisotropic binding and this could be
involved in the lack of transcriptional activation. However,
a different conformation of the heterodimer bound to DRE and
DRs elements could also affect interaction with coregulators,
which are required for ligand-dependent transcription by nuc-
lear receptors. This appears to be the case, because reduced
recruitment of p160 coactivators by the RXR/VDR hetero-
dimer bound to the DRE was found. Therefore, a combination
of reduced binding affinity and abnormal association with
coactivators could explain the lack of transcriptional activity
of the RXR/VDR heterodimer upon binding to the DRE.
In summary, our results demonstrate a new function for
DREAM acting as a transcriptional stimulator. The existence
of a transcriptional cross-talk between DREAM and the
nuclear receptor signaling, in which both protein–DNA and
protein–protein interactions could participate, may have an
important physiological relevance. Our results indicate that
genes, such as RARb2 or p21cip1, could be targets for
DREAM. Future studies will be needed to identify additional
genes in DREAM expressing tissues, which contain HRE-like
DREAM binding sites and are regulated by this transcription
factor.
Figure 9. Recruitment of coactivators by the VDR/RXR heterodimer. Gel
retardation assays with the DR3 (A) and the DRE (B), and in vitro translated
VDR and RXR (3 ml). The assays were performed in the presence of 600 ng of
GST alone or the same amount of the RIDs of p160 coactivators SRC-1, ACTR
and TIF-2 fused to GST. When indicated (+), vitamin D (100 nM) was present in
the binding reactions. Arrowheads, mobilities of the supershifted complexes
containing the receptor heterodimer and the coactivator. Autoradiogram in the
right has been subjected to a longer exposure time.
Figure 8. Vitamin D and retinoic acid receptors do not affect DRE-mediated
transcription. HeLa cells were transfected with the CAT reporter construct
pHD3 containing sequences 151/+150 of the human prodynorphin promoter,
or pHD3mut mutated in the DRE site. The reporter plasmids were cotrans-
fected with expression vectors for VDR (A) or RAR (B), and CAT activity
determined after incubation with vitamin D or RA as indicated. (C) Cells were
cotransfected with plasmids containing the DRE and DR3 motifs upstream and
downstream of the TK promoter and with an expression vector for VDR. CAT
activity was determined in untreated and vitamin D-treated cells.
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